Two Novocure CEO presentations will have live audio webcasts and replays for at least 14 days.
Novocure (Nasdaq: NVCR) announced that its CEO, Frank Leonard, will participate in two upcoming investor conferences: the Piper Sandler 38th Annual Healthcare Conference on December 1, 2026, and the 9th Annual Evercore Healthcare Conference on December 2, 2026. Live audio webcasts of his fireside chats will be available on Novocure's Investor Relations website and for replay for at least 14 days. Novocure is an oncology company focused on Tumor Treating Fields therapy for aggressive cancers.
NovoCure Ltd (038.SG) Seasonal returns chart
The article presents a seasonal returns chart for NovoCure Ltd (038.SG), displaying the average monthly price return from 2017 to 2026. The stock closed at 10.69 EUR, showing a 1.04% increase on November 13th. This information is available through Yahoo Finance, which provides market data and financial tools.
In a pancreatic cancer trial, adding Novocure's therapy to chemotherapy improved survival and quality of life.
Novocure announced that JAMA Network Open published the results of a secondary analysis from its Phase 3 PANOVA-3 trial for pancreatic cancer. The study found that combining Novocure's Tumor Treating Fields (TTFields) therapy with chemotherapy significantly improved overall survival, pain outcomes, and quality of life for patients. The therapy was well-tolerated, with mild to moderate skin adverse events being the most common device-related side effects.
Did FDA Rejection Of Optune Mya Just Shift NovoCure Stock Narrative?
NovoCure recently received a Not Approvable Letter from the FDA for its Optune Mya application, citing uncertainty over clinical benefit for brain metastases. This rejection shifts the investment narrative, placing more pressure on existing GBM usage and other commercial launches for growth. Analysts had previously seen expansion into new indications like brain metastases as a core pillar for widening NovoCure's addressable market and achieving profitability.
Is NovoCure (NVCR) Below Fair Value Following The FDA Optune Mya Setback?
NovoCure (NVCR) recently received a "Not Approvable Letter" from the FDA for its Optune Mya device, causing a short-term stock price decline. Despite this setback, Simply Wall St's analyst consensus places NovoCure's fair value at $26.86, significantly above its current share price of US$11.99, suggesting it is undervalued. The company's future growth hinges on the success of other TTFields therapy indications and resolving ongoing legal investigations.
FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.
NovoCure's stock took a hit after the FDA issued a "not approvable" letter for its investigational device, Optune Mya, intended for lung cancer brain metastases. While the device met its primary endpoint, it fell short on key secondary endpoints, leading to the FDA's decision based on "uncertainty around the degree of clinical benefit." The company plans to evaluate the response and seek a path to approval, but analysts express skepticism about the stock as other Optune products mature and new competitors emerge.
Wedbush maintains NovoCure at Neutral, lowers price target to $19 from $20
Wedbush has reiterated its "Neutral" rating for NovoCure (NVCR) while decreasing its price target from $20 to $19, a 5.0% reduction. This new price target suggests a 51.6% upside from NovoCure's closing price of $12.53 on November 9. Investors can find more detailed price target data and analyst recommendations on TradingView's platform.
NovoCure Ltd (038.DU) Seasonal returns chart
The article presents a seasonal returns chart for NovoCure Ltd (038.DU), displaying the average monthly price return from 2020 to 2026. As of the delayed quote, NovoCure Ltd's stock was trading at 11.03 EUR, down 6.33%. The market was open at 8:13:12 am GMT+1.
Novocure Stock Slips After FDA Rejects Its Cancer Treatment Device
Novocure's stock declined after the FDA issued a Not Approvable Letter for its Optune Mya device, intended for brain metastases from non-small cell lung cancer, due to uncertainty regarding clinical benefit. This regulatory setback follows disappointing results from its Phase 3 TRIDENT study for newly diagnosed glioblastoma, which failed to meet its primary endpoint. Despite the regulatory challenges, Novocure reported strong quarterly revenues and raised its fiscal 2026 sales guidance.
FDA rejects Novocure's Optune Mya tumor treating fields device for lung cancer brain metastases
The FDA has declined to approve Novocure's Optune Mya device for non-small cell lung cancer that has spread to the brain, citing uncertainty around its clinical benefit. While the Phase 3 METIS trial showed the device delayed intracranial progression, it did not improve overall survival or neurocognitive outcomes. This decision is a setback for Novocure's planned early 2027 launch, though the company is evaluating feedback and intends to meet with the FDA.
Novocure Stock Slips After FDA Rejects Its Cancer Treatment Device
Novocure Ltd. (NASDAQ: NVCR) experienced a stock decline after the FDA issued a Not Approvable Letter for its Optune Mya device, intended for brain metastases from non-small cell lung cancer. The FDA cited uncertainty regarding the clinical benefit. This regulatory setback follows a previous Phase 3 TRIDENT study that failed to significantly improve overall survival in glioblastoma patients.
Novocure denied FDA approval for metastatic cancer treatment
Novocure has been denied FDA approval for its Optune Mya device, intended to treat non-small cell lung cancer that has spread to the brain. The FDA cited uncertainty regarding the degree of clinical benefit, despite not raising safety concerns. Novocure plans to meet with the FDA to explore options for approval without additional clinical studies.
NovoCure (NVCR): FDA issued a Not Approvable Letter for Optune Mya...
The FDA has issued a Not Approvable Letter to NovoCure (NVCR) for Optune Mya in treating brain metastases from NSCLC, citing uncertain clinical benefit despite no safety concerns. This decision was revealed in an SEC Form 8-K filing. Historically, NovoCure's stock has shown mixed reactions to previous headlines, with a median move of 4.2% in either direction.
Novocure receives FDA rejection for brain cancer treatment By Investing.com
Novocure received a Not Approvable Letter from the FDA for its Optune Mya application, intended for treating adult patients with brain metastases from non-small cell lung cancer. The FDA cited uncertainty regarding the clinical benefit of Optune Mya as the reason for rejection, although no safety concerns were raised. Novocure plans to engage with the FDA to explore options for approval without additional clinical studies.
US FDA declines to approve Novocure's lung cancer device
The US Food and Drug Administration has declined to approve Novocure's Optune Mya device, designed for lung cancer patients with brain metastases, citing uncertainty about its clinical benefit. While no safety concerns were raised, preliminary results from a 2024 trial showed the device delayed brain tumor growth but did not achieve statistical significance for overall survival. Novocure plans to engage with the FDA to explore options for approval without requiring additional clinical studies.
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer
Novocure (Nasdaq: NVCR) announced it received a Not Approvable Letter from the U.S. FDA for its Optune Mya® Premarket Approval application for treating brain metastases from non-small cell lung cancer. The FDA cited uncertainty regarding clinical benefit, though no safety concerns were raised. Novocure plans to engage with the FDA to explore options for approval without additional clinical studies.
Form 8-K NovoCure Ltd For: Nov 09
NovoCure Limited announced that its Premarket Approval (PMA) application for Optune Mya® for treating brain metastases from non-small cell lung cancer was rejected by the U.S. FDA. The FDA cited uncertainty regarding the degree of clinical benefit, but had no safety concerns. NovoCure plans to discuss options with the FDA to pursue approval without additional clinical studies.
NovoCure Stock In Focus After Revenue Guidance Raise And Quarterly Sales Update
NovoCure has increased its 2026 revenue guidance to US$736 million - US$743 million and reported third-quarter 2026 sales of US$193.4 million, with a narrowed net loss of US$10.44 million. This positive outlook is supported by a new collaboration with Verastem Oncology for a pancreatic cancer trial, aiming to expand the application of its Tumor Treating Fields (TTFields) therapy. The company's focus remains on gaining traction in multiple cancer indications and achieving sustainable profitability despite ongoing challenges with its Optune Pax therapy and legal costs.
NovoCure (NVCR) Following Raised 2026 Guidance What Does Valuation Say
NovoCure (NVCR) recently raised its 2026 net revenue outlook to US$736 million to US$743 million, following stronger third-quarter results. Despite a recent 8.79% share price jump, longer-term returns have been mixed, with a 5-year decline of 85.81%. The company is considered 46% undervalued against a fair value of $26.86, with analysts forecasting revenue growth to $1.2 billion by 2029, though risks like slowing Optune Pax adoption and legal investigations exist.
NovoCure Ltd (038.SG) Seasonal returns chart - Yahoo Finance
The article provides a seasonal returns chart for NovoCure Ltd (038.SG) on Yahoo Finance. It displays the average monthly price return for the company between 2017 and 2026. The stock closed at 11.88 EUR, down 1.45% on November 6, 2026.
NovoCure Ltd (038.MU) Seasonal returns chart - Yahoo Finance
The Yahoo Finance page displays the seasonal returns chart for NovoCure Ltd (038.MU), showing its average monthly price return from 2018 to 2026. The stock is listed at 11.89 EUR, with no change reported at the close of November 4th. The page includes market data for various global indices and cryptocurrencies.
NovoCure Ltd (038.MU) Seasonal Returns Chart - Yahoo Finance
The article displays a seasonal returns chart for NovoCure Ltd (038.MU) on Yahoo Finance. It shows the average monthly price return for the company between 2018 and 2026. The stock was quoted at 12.43 EUR, down 1.35% at the close on November 6.
NovoCure Earnings Call Signals Growth and Profitability Momentum
NovoCure Ltd. (NVCR) reported strong Q3 2026 results, highlighted by record GBM patient growth, 16% year-over-year revenue increase to €193 million, and significant profitability improvements, narrowing its net loss to $10 million. The company emphasized momentum in Japan for Optune Lua, while acknowledging a slowdown in OptunePax's U.S. launch due to other market demands. NovoCure also raised its 2026 net revenue guidance and reaffirmed its commitment to double-digit growth and achieving full-year adjusted EBITDA breakeven.
Weekly Recap: Raised 2026 guidance and METIS trial success, FDA filing
NovoCure Ltd. (NASDAQ:NVCR) reported a 16% increase in Q3 revenue to $193.4 million, narrowed losses, and raised its 2026 guidance, driven by the success of its METIS trial and Japan's approval of Optune Pax. Despite these advancements, U.S. active users declined due to Daraxonrasib-related access issues, leading analysts to lower price targets, while NovoCure also plans a 2027 KRAS combination trial. The METIS trial met its primary endpoint, leading to an FDA filing for Optune Mya to treat brain metastases from lung cancer.
NovoCure Limited (NASDAQ:NVCR) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
NovoCure Limited recently released strong third-quarter results, with revenues exceeding analyst forecasts by 6.1% at US$193m and statutory losses per share being 6.1% smaller than expected. Analysts are now predicting revenues of US$808.3m in 2027, an 11% improvement, and a significant reduction in loss per share to US$0.77. Despite a modest increase in sentiment regarding losses, the average price target remained steady at US$26.43, indicating performance in line with expectations.
Novocure Ltd earnings beat by $0.14, revenue topped estimates
Novocure Ltd (NASDAQ: NVCR) reported third-quarter earnings per share of $-0.09, surpassing analyst estimates by $0.14, and revenue of $193.39 million, exceeding the consensus of $182.28 million. The company also provided a positive FY 2026 revenue guidance between $736.00 million and $743.00 million, higher than analyst expectations. Novocure's stock has seen a 10.53% increase over the last 12 months, with its financial health rated as "good performance" by InvestingPro.
Wells Fargo maintains NovoCure at Equal-Weight, lowers price target to $15 from $20
Wells Fargo has reaffirmed its "Equal-Weight" rating for NovoCure but has reduced its price target to $15 from $20, a 25% decrease. This new price target suggests a potential upside of 14.4% from NovoCure's closing price of $13.11 on October 29. The adjustment reflects the bank's updated outlook on the company's valuation.
NovoCure Ltd. Trade Ideas — BSESOF:038
This article compiles several trade ideas for NovoCure Ltd. (BSESOF:038 / NASDAQ:NVCR) from various traders on TradingView. The ideas include both long and short positions, based on technical analysis patterns like cup and handle, breakouts, pullbacks, and bear flags, as well as fundamental considerations like past performance and recent insider selling.
NovoCure Q3 Revenue Rises 16% to $193.4M, Raises 2026 Guidance
NovoCure reported a 16% increase in third-quarter 2026 revenue to $193.4 million, with a net loss of $10.4 million. The company also raised its full-year 2026 revenue and adjusted EBITDA guidance. Key business highlights include growth in active patients for Optune Gio and Optune Lua, regulatory approval for Optune Pax in Japan for pancreatic cancer, and ongoing clinical trial developments.
Return on equity % of NovoCure Ltd. – BSESOF:038
The article provides a financial metric for NovoCure Ltd. (BSESOF:038), specifically its "Return on equity %". It appears to be a stub or placeholder from a financial data platform like TradingView, indicating that the market is closed with no trades recorded. The content primarily focuses on the company's identifier and the financial metric.
NovoCure Q3 2026 Earnings Call Transcript
NovoCure reported record high quarterly net revenue of $193 million for Q3 2026, a 16% year-over-year increase, driven by a 19% increase in active patients. The company raised its full-year 2026 net revenue guidance and achieved adjusted EBITDA positivity, with strategic investments in R&D ongoing. Despite challenges in the U.S. launch of Optune Pax, the company remains confident in its path to profitability and sees strong momentum in Optune Geo and Optune Lua in Japan.
Novocure CEO Says RVMD’s Daraxonrasib Slowed Optune Pax Adoption – Wedbush Sees Disruption Rather Than Direct Competition
Novocure's CEO stated that Revolution Medicines' Daraxonrasib has slowed the adoption of its Optune Pax device, leading to a decline in U.S. patients using Optune Pax in Q3. Wedbush, however, views this impact as disruption in medical practices rather than direct displacement. Despite these challenges, Novocure raised its full-year 2026 revenue guidance and reported increased Q3 revenue, beating Wall Street estimates.
NovoCure Q3 Revenue Rises 16% to $193.4M, Raises 2026 Guidance
NovoCure reported a 16% year-over-year increase in third-quarter 2026 revenue, reaching $193.4 million, despite a net loss of $10.4 million. The company also raised its full-year 2026 revenue guidance to $736 million–$743 million and adjusted EBITDA guidance to $24 million–$34 million. Key business highlights include growth in active patients for its Optune Gio and Optune Lua therapies, approval for Optune Pax in Japan for pancreatic cancer, and anticipated FDA decisions and trial enrollments for other therapies.
Novocure Ltd earnings beat by $0.14, revenue topped estimates
Novocure Ltd (NASDAQ: NVCR) reported third-quarter EPS of $-0.09, exceeding analyst estimates by $0.14. The company also surpassed revenue expectations, bringing in $193.39M against a consensus of $182.28M. Novocure provided FY 2026 revenue guidance between $736.00M and $743.00M, which is above analyst consensus.
Revenue rises 16% at NovoCure (NVCR), but it still posts a quarterly loss.
NovoCure (NVCR) reported a 16% increase in third-quarter 2026 revenue to $193.4 million, with active patients growing to 5,260. Despite the revenue growth, the company posted a net loss of $10.4 million, though this was narrower than the previous year's $37.3 million loss. The increase in revenue was primarily driven by active patient growth and one-time benefits from approval rate increases in key markets.
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
Novocure announced a clinical trial collaboration with Verastem Oncology to evaluate Tumor Treating Fields (TTFields) therapy in combination with chemotherapy and Verastem's investigational KRAS G12D inhibitor, VS-7375, for locally advanced pancreatic cancer. Novocure will fund and manage the trial operations, while Verastem will supply the drug. This collaboration aims to explore a novel treatment approach for this challenging cancer, with the trial expected to enroll approximately 25 patients starting in 2027.
NovoCure Limited Estimates – NASDAQ:NVCR
This article provides an overview of NovoCure Limited (NASDAQ: NVCR) financial estimates available on TradingView. It directs users to explore reported financial data and analyst estimates for the income statement, balance sheet, cash flow statement, and valuation metrics, allowing comparison of actual results with average, high, and low estimates, and visualization of trends over time. The article also includes a disclaimer stating that the information is not investment advice.
Novocure Must Show Its Breakout Second Quarter Was A Trend, Not A One-Off
Novocure faces an awkward contradiction as its stock has fallen despite raised revenue outlooks and improved profitability. The upcoming third-quarter report on October 29 will be crucial to determine if the second quarter's strong performance was a sustainable trend or a one-off event. The market is looking for evidence of continued growth in its core OptuneGeo franchise and the newer OptunePax pancreatic launch, along with stable profitability, to convince skeptics.
2026 Best Companies to Work For Hall of Fame: Novocure
Novocure has been inducted into the 2026 Best Companies to Work For Hall of Fame by Business NH Magazine, recognized for its comprehensive employee well-being programs. The company offers extensive benefits including a wellness program that rewards healthy activities, generous health plans covering mental health and fertility, tuition reimbursement, and flexible work options like NovoFlex and paid parental leave. These initiatives underscore Novocure's commitment to supporting its 1,600 employees, with 282 based in New Hampshire.
Wall Street Zen downgrades NovoCure stock to Hold
Wall Street Zen has downgraded NovoCure stock from Buy to Hold following the company's second-quarter revenue of $183.58 million and the recent Japanese approval of Optune Pax. Despite the approval and an increase in adjusted EBITDA, the company faces scrutiny as it approaches its Q3 2026 earnings release on October 29, 2026. The stock is currently trading at EUR 12.33, with an average target price of USD 21.20 cited by MarketBeat.
Is NovoCure (NVCR) Undervalued Following Its Japan Approval For Optune Pax?
NovoCure (NVCR) recently received Japanese regulatory approval for its Optune Pax device for pancreatic cancer, yet its share price has seen short-term declines despite year-to-date and one-year gains. The company is considered 71% undervalued with a fair value of $48.80 against a current price of $14.30, supported by positive adjusted EBITDA guidance and a strong cash balance. However, risks such as ongoing GAAP losses and legal costs could undermine this bull case.
Is NovoCure (NVCR) Undervalued Following Its Japan Approval For Optune Pax?
NovoCure (NVCR) recently received approval in Japan for Optune Pax to treat pancreatic cancer, despite its share price having seen short-term declines but an increase year-to-date. The company is considered 71% undervalued by most analysts, with a fair value of $48.80 against a current price of $14.30, supported by positive adjusted EBITDA and a strong cash balance. However, risks such as ongoing GAAP losses and legal costs could impact this valuation.
Wall Street Zen downgrades Novocure stock to Hold
Wall Street Zen has downgraded Novocure stock from Buy to Hold, citing a consensus target of USD 21.20. This comes after Novocure reported a 16% year-over-year increase in Q2 2026 revenue to USD 184.00 million and raised its full-year 2026 revenue guidance. The company also saw FDA approval for Optune Pax for pancreatic cancer and will report Q3 2026 results on October 29, 2026.
Did Japan Pancreatic Cancer Approval Just Shift NovoCure's (NVCR) Investment Narrative?
Japan’s Ministry of Health, Labour and Welfare has approved NovoCure’s Optune Pax device for pancreatic cancer, based on positive Phase 3 PANOVA 3 survival data. This approval expands NovoCure's market and validates its Tumor Treating Fields (TTFields) technology, supporting the company's long-term growth thesis. While it diversifies geographical and indication reach, the immediate impact on profitability depends on adoption and reimbursement in larger markets, and analysts will monitor its effect on ongoing trials and future applications.
Did Japan Pancreatic Cancer Approval Just Shift NovoCure's (NVCR) Investment Narrative?
Japan's Ministry of Health, Labour and Welfare has approved NovoCure's Optune Pax device for pancreatic cancer, expanding the addressable patient pool for its Tumor Treating Fields (TTFields) technology. This approval, based on positive Phase 3 PANOVA 3 survival data, supports NovoCure's thesis of TTFields as a broad oncology platform and could influence investor perception. While it diversifies geography and indications, questions regarding consistent profitability and slow prescription growth in existing markets remain, with analysts forecasting significant revenue and earnings growth by 2029.
Insiders At NovoCure Sold US$3.3m In Stock, Alluding To Potential Weakness
Insiders at NovoCure recently sold US$3.3 million worth of stock, raising concerns about the company's future performance. This significant sell-off by multiple insiders, especially when the stock is trading below its intrinsic value, often signals potential weakness or a belief that the share price may decline. Investors commonly monitor insider selling as a bearish indicator.
Novocure received Japan approval. Novocure stock fell 4.51 percent
Novocure received Japanese approval for its Optune Pax device to treat locally advanced pancreatic cancer. Despite this positive regulatory news, Novocure's stock fell by 4.51 percent. The company's second-quarter revenue was USD 183.58 million, and it reported an adjusted loss per share of USD 0.13.
NovoCure (NVDA) Could Be 69% Undervalued After Japan Pancreatic Cancer Approval
NovoCure (NVCR) recently received Japanese regulatory approval for its Optune Pax device to treat pancreatic cancer, yet its shares trade at a significant discount to analyst targets. Despite recent stock price declines, the company's pioneering device-based therapy for cancer, along with efforts to improve operational efficiency, suggests potential for future profitability and sustained revenue growth, leading some to believe it is 69% undervalued. However, its success hinges on flawless execution and favorable reimbursement decisions.
NovoCure (NVDA) Could Be 69% Undervalued After Japan Pancreatic Cancer Approval
NovoCure recently received regulatory approval in Japan for its Optune Pax device for pancreatic cancer, but its shares have seen a recent decline. Despite this, analysts suggest the company could be significantly undervalued, with a fair value estimate near $48.93, citing its pioneering non-invasive therapy and potential for long-duration revenue growth. The article also highlights the importance of flawless execution and offers resources for further investment research.
NovoCure Limited (NVCRN.MX) Analyst Insights, Price Targets & Recommendations
This article provides an overview of analyst ratings and price targets for NovoCure Limited (NVCRN.MX). It lists recent upgrades and downgrades from various financial institutions, including Wedbush, HC Wainwright & Co., Wells Fargo, and Evercore ISI Group. The current stock price and performance are also displayed.